Skip to main content
James M. Hoffman, PharmD, MS
James M. Hoffman, PharmD, MS

James M. Hoffman, PharmD, MS

Member, St. Jude Faculty

  • Senior Vice President, Quality and Safety
  • Chief Patient Safety Officer



BS – Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania
PharmD – Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania
MS – School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin

Honors & Awards

  • 2016  American Pharmacists Association (APhA) Foundation Pinnacle Award -- Individual Award for Career Achievement
  • 2015  American Society of Health-System Pharmacists (ASHP) Foundation Literature Award for Innovation in Pharmacy Practice
  • 2013  Fellow, American Society of Health-System Pharmacists
  • 2013  St. Jude Clinical Care Improvement Award (with St. Jude Medication Use Safety Team)

Research Interests

  • Medication safety and outcomes
  • Patient safety event detection and reporting systems
  • Patient safety culture and just culture
  • Clinical decision support in the electronic medical record

Selected Publications

Haidar CE, Petry N, Oxencis C, Douglas JS, Hoffman JM. ASHP statement on the pharmacist's role in clinical pharmacogenomics. Am J Health Syst Pharm Apr 1;79(8):704-707, 2022.

Terao M, Stokes CL, Sitthi-Amorn J, Vinitsky A, Burlison JD, Baker JN, Li C, Lu Z, McDonald M, Hoffman JM. Quality improvement knowledge in pediatric hematology/oncology physicians: A need for improved education. Pediatr Blood Cancer Aug 1;69(8):e29794,2022.

Tang L, Hijano DR, Gaur AH, Geiger TL, Neufeld EJ, Hoffman JM, Hayden RT. Asymptomatic and symptomatic SARS-CoV-2 infections after BNT162b2 vaccination in a routinely screened workforce. JAMA Jun 22;325(24):2500-2502, 2021.

Burlison JD, Quillivan RR, Scott SD, Johnson S, Hoffman JM. The effects of the second victim phenomenon on work-related outcomes: Connecting self-reported caregiver distress to turnover intentions and absenteeism. J Patient Saf .Apr 1;17(3):195-199, 2021. doi: 10.1097/PTS.0000000000000301.

Blazin LJ, Sitthi-Amorn J, Hoffman JM, Burlison JD. Improving patient handoffs and transitions through adaptation and implementation of I-PASS across multiple handoff settings.  Pediatr Qual Saf Jul 23;5(4):e323, 2020. doi: 10.1097/pq9.0000000000000323. eCollection Jul-Aug 2020.

Relling MV, Klein TE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Caudle KE. The Clinical Pharmacogenetics Implementation Consortium: 10 years later. Clin Pharmacol Ther Jan;107(1):171-175, 2020. doi: 10.1002/cpt.1651. Epub Nov 5, 2019.

Haidar CE, Relling MV, Hoffman JM. Preemptively Precise: Returning and Updating Pharmacogenetic Test Results to Realize the Benefits of Preemptive Testing. Clin Pharmacol Ther Nov;106(5):942-944, 2019. doi: 10.1002/cpt.1613. (Epub Sep 14, 2019.)

Keeling NJ, Rosenthal MM, West-Strum D, Patel AS, Haidar CE, Hoffman JM. Preemptive pharmacogenetic testing: Exploring the knowledge and perspectives of US payers. Genet Med May;21(5):1224-1232, 2019. doi: 10.1038/gim.2017.181. Epub Oct 26, 2017.

Daniels CC, Burlison JD, Baker DK, Robertson J, Sablauer A, Flynn PM, Campbell PK, Hoffman JM. Optimizing drug-drug interaction alerts using a multidimensional approach. Pediatrics February 13, 2019.

Hoffman JM, Keeling NJ, Forrest CB, Tubbs-Cooley HL, Moore E, Oehler E, Wilson S, Schainker E, Walsh KE. Priorities for pediatric patient safety research. Pediatrics January 23, 2019.

Caudle KE, Keeling NJ, Klein TE, Whirl-Carrillo M, Pratt VM, Hoffman JM. Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. Pharmacogenomics 2018 Jun 19. doi: 10.2217/pgs-2018-0028. [Epub ahead of print]

Keeling NJ, Rosenthal MM, West-Strum D, Patel AS, Haidar CE, Hoffman JM. Preemptive pharmacogenetic testing: Exploring the knowledge and perspectives of US payers. Genet Med Oct 2017.

Hicks JK, Dunnenberger HM, Gumpper KF, Haidar CE, Hoffman JM. Integrating pharmacogenomics into electronic health records with clinical decision support. Am J Health Syst Pharm 73(23):1967-1976, 2016.

Burlison JD, Quillivan RR, Kath LM, Zhou Y, Courtney SC, Cheng C, Hoffman JM. A multilevel analysis of U.S. hospital patient safety culture relationships with perceptions of voluntary event reporting. J Patient Saf November 3, 2016. PMID: 27820722

Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, Relling MV, Hoffman JM. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med July 21, 2016. Epub ahead of print. doi: 10.1038/gim.2016.87.

Gammal RS, Crews KR, Haidar CE, Hoffman JM, Baker DK, Barker PJ, Estepp JH, Pei D, Broeckel U, Wang W, Weiss MJ, Relling MV, Hankins J. Pharmacogenetics for safe codeine use in sickle cell disease. Pediatrics 138(1):e20153479, 2016.

Hoffman JM, Dunnenberger HM, Kevin Hicks J, Caudle KE, Whirl Carrillo M, Freimuth RR, Williams MS, Klein TE, Peterson JF. Developing knowledge resources to support precision medicine: principles from the Clinical pharmacogenetics Implementation Consortium (CPIC). J Am Med Inform Assoc 23(4):796-801, 2016.

McDaniel RB, Burlison JD, Baker DK, Hasan M, Robertson J, Hartford C, Howard SC, Sablauer A, Hoffman JM. Alert dwell time: introduction of a measure to evaluate interruptive clinical decision support alerts. J Am Med Inform Assoc 23(e1):e138-41, 2016.

Goldspiel BR, DeChristoforo R, Hoffman JM. Preventing chemotherapy errors: Updating guidelines to meet new challenges. Am J Health Syst Pharm 72(8):668-9, 2015.

Burlison JD, Scott SD, Browne EK, Thompson SG, Hoffman JM. The Second Victim Experience and Support Tool: Validation of an Organizational Resource for Assessing Second Victim Effects and the Quality of Support Resources. J Patient Saf August 26, 2014. Epub ahead of print. doi: 10.1097/PTS.0000000000000129.

Call RJ, Burlison JD, Robertson JJ, Scott JR, Baker DK, Rossi MG, Howard SC, Hoffman JM. Adverse drug event detection in pediatric oncology and hematology patients: using medication triggers to identify patient harm in a specialized pediatric patient population. J Pediatr 165(3):447-52, 2014.

Hoffman JM, Haidar CE, Wilkinson MR, Crews KR, Baker DK, Kornegay NM, Yang W, Pui CH, Reiss UM, Gaur AH, Howard SC, Evans WE, Broeckel U, Relling MV. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet 166(1):45-55, 2014.

Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, Hicks JK, Wilkinson MR, Haas DW, Kroetz DL. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for HLA-B genotype and abacavir dosing: 2014 update. Clin Pharmacol Ther 95(5):499-500, 2014.

Petschonek S, Burlison J, Cross C, Martin K, Laver J, Landis RS, Hoffman JM. Development of the Just Culture Assessment Tool: measuring the perceptions of health-care professionals in hospitals. J Patient Saf 9(4):190-7, 2013.

Bell GC, Crews KR, Wilkinson MR, Haidar CE, Hicks JK, Baker DK, Kornegay NM, Yang W, Cross SJ, Howard SC, Freimuth RR, Evans WE, Broeckel U, Relling MV, Hoffman JM. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc 21(e1):e93-9, 2014.

McBride A, Holle LM, Westendorf C, Sidebottom M, Griffith N, Muller RJ, Hoffman JM. National survey on the effect of oncology drug shortages on cancer care. Am J Health Syst Pharm 70(7):609-17, 2013.

Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, Lorier R, Stoddard A, Yang W, Smith C,Fernandez CA, Cross SJ, Haidar C, Baker DK, Howard SC, Evans WE, Broeckel U, Relling MV. A clinician driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharm Ther 92(5):563-566, 2012.

Hoffman JM, Li E, Doloresco F, Matusiak L, Hunkler RJ, Shah ND, Vermeulen LC, Schumock GT. Projecting future drug expenditures--2012. Am J Health Syst Phar 69(5):405-421, 2012.

Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH, Markus R, Matulonis UA, Reinke D, Li EC, DeMartino+ J, Larsen JK,Hoffman JM. NCCN Biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw 9(suppl 4):S1-22, 2011.

Hoffman JM, Baker DK, Howard SC, Laver JH, Shenep JL. Safe and Successful Implementation of CPOE for Chemotherapy at a Children’s Cancer Center. J Natl Compr Canc Netw 9:S36-50, 2011.

Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, Mullins R, Relling MV, Hoffman JM. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 68:143-50, 2011.

Stubbings JA, Joshi R, Hoffman JM. Risk evaluation and mitigation strategies (REMS): Challenges and opportunities for pharmacists. Am J Health Syst Pharm 67:1454-1547, 2010.

Adderson EE, Flynn PM, Hoffman JM. Efficacy and safety of cefepime in pediatric patients: a systematic review and meta-analysis. J Pediatr 157(3):490-495, 2010.

Gaur AH, Bagga B, Barman S, Hayden R, Lamptey A, Hoffman JM, Bhojwani D, Flynn PM, Tuomanen E, Webby R. Intravenous Zanamivir for Oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 362(1):88-89, 2010.

Last update: July 2023